ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer.

Jeong, Dawoon; Ham, Juyeon; Kim, Hyeon Woo; Kim, Heejoo; Ji, Hwee Won; Yun, Sung Hwan; Park, Jae Eun; Lee, Keun Seok; Jo, Heein; Han, Jai Hong; Jung, So-Youn; Lee, Seeyoun; Lee, Eun Sook; Kang, Han-Sung; Kim, Sun Jung

Jeong, Dawoon; Ham, Juyeon; Kim, Hyeon Woo; Kim, Heejoo; Ji, Hwee Won; Yun, Sung Hwan; Park, Jae Eun; Lee, Keun Seok; Jo, Heein; Han, Jai Hong; Jung, So-Youn; Lee, Seeyoun; Lee, Eun Sook; Kang, Han-Sung; Kim, Sun Jung.

Afiliação

Jeong D; Department of Life Science, Dongguk University-Seoul Goyang, Republic of Korea.
Ham J; Current address: Aprogen Sungnam 13215, Republic of Korea.
Kim HW; Department of Life Science, Dongguk University-Seoul Goyang, Republic of Korea.
Kim H; Current address: Kogene Biotech Seoul 08507, Republic of Korea.
Ji HW; Department of Life Science, Dongguk University-Seoul Goyang, Republic of Korea.
Yun SH; Department of Life Science, Dongguk University-Seoul Goyang, Republic of Korea.
Park JE; Department of Life Science, Dongguk University-Seoul Goyang, Republic of Korea.
Lee KS; Department of Life Science, Dongguk University-Seoul Goyang, Republic of Korea.
Jo H; Department of Life Science, Dongguk University-Seoul Goyang, Republic of Korea.
Han JH; Research Institute and Hospital, National Cancer Center Goyang, Republic of Korea.
Jung SY; Research Institute and Hospital, National Cancer Center Goyang, Republic of Korea.
Lee S; Research Institute and Hospital, National Cancer Center Goyang, Republic of Korea.
Lee ES; Research Institute and Hospital, National Cancer Center Goyang, Republic of Korea.
Kang HS; Research Institute and Hospital, National Cancer Center Goyang, Republic of Korea.
Kim SJ; Research Institute and Hospital, National Cancer Center Goyang, Republic of Korea.